No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 43.940
- +1.370+3.22%
Trading May 3 09:46 ET
2.76BMarket Cap-60191P/E (TTM)
43.970High43.405Low31.16KVolume43.510Open42.570Pre Close1.36MTurnover0.13%Turnover RatioLossP/E (Static)62.87MShares64.98052wk High5.57P/B1.03BFloat Cap24.31052wk Low--Dividend TTM23.47MShs Float64.980Historical High--Div YieldTTM1.33%Amplitude4.250Historical Low43.737Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
MoonLake Immunotherapeutics' Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating
Strong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market Potential
MoonLake Immunotherapeutics: A Promising Outlook With Sonelokimab's Potential in the HS Market
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimab
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.
HC Wainwright & Co. : MoonLake (MLTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $100.00.
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg